Skip to main content
. Author manuscript; available in PMC: 2022 Aug 16.
Published in final edited form as: Cancer Res Commun. 2022 Jul 26;2022:10.1158/2767-9764.CRC-21-0143. doi: 10.1158/2767-9764.CRC-21-0143

Figure 3. Best overall response by PD-L1.

Figure 3.

ORR data by race/ethnic group for NSCLC patients treated with ICI monotherapy stratified by PD-L1 A) ≥50%, B) 1–49% and C) 0% . CR- complete response; PR- partial response; SD- stable disease; PD- progressive disease.